Cristina Poveda Cuevas

Dr. Cristina Poveda Cuevas

Baylor College of Medicine, Houston, TX, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2014 in Infection, Genetics and Evolution
Verified
Journal Article
Closed access
JRJuan David Ramírez
Juan David Ramírez
GTGabriela Tapia-Calle
Gabriela Tapia-Calle
GMGeissler Muñoz-Cruz
Geissler Muñoz-Cruz
CCCristina Poveda Cuevas
Cristina Poveda Cuevas
LRLina M. Rendón
Lina M. Rendón
FGFelipe Guhl
Felipe Guhl

7 March 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CCCristina Poveda Cuevas
Cristina Poveda Cuevas
MFManuel Fresno
Manuel Fresno
Núria GironèsNúria Gironès
Núria Gironès
OMOlindo Martins-filho
Olindo Martins-filho
JRJuan David Ramírez
Juan David Ramírez
FGFelipe Guhl
Felipe Guhl
Chagas disease caused by the protozoan Trypanosoma cruzi is an important public health problem in Latin America. The immunological mechanisms involved in Chagas disease pathogenesis remain incompletely elucidated. The aim of this study was to explore cytokine profiles and their possible association to the infecting DTU and the pathogenesis of Chagas disease. 109 sero-positive T. cruzi patients and 21 negative controls from Bolivia and Colombia, were included. Flow cytometry assays for 13 cytokines were conducted on human sera. Patients were divided into two groups: in one we compared the quantification of cytokines between patients with and without chronic cardiomyopathy; in second group we compared the levels of cytokines and the genetic variability of T. cruzi. Significant difference in anti-inflammatory and pro-inflammatory cytokines profiles was observed between the two groups cardiac and non-cardiac. Moreover, serum levels of IFN-γ, IL-12, IL-22 and IL-10 presented an association with the genetic variability of T.cruzi, with significant differences in TcI and mixed infections TcI/TcII. Expression of anti-inflammatory and pro-inflammatory cytokines may play a relevant role in determining the clinical presentation of chronic patients with Chagas disease and suggests the occurrence of specific immune responses, probably associated to different T. cruzi DTUs.

20 November 2014 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
Núria GironèsNúria Gironès
Núria Gironès
SCSofía Carbajosa
Sofía Carbajosa
NGNéstor A Guerrero
Néstor A Guerrero
CCCristina Poveda Cuevas
Cristina Poveda Cuevas
CCCarlos Chillón-Marinas
Carlos Chillón-Marinas
MFManuel Fresno
Manuel Fresno
Chagas disease is caused by Trypanosoma cruzi infection, being cardiomyopathy the more frequent manifestation. New chemotherapeutic drugs are needed but there are no good biomarkers for monitoring treatment efficacy. There is growing evidence linking immune response and metabolism in inflammatory processes and specifically in Chagas disease. Thus, some metabolites are able to enhance and/or inhibit the immune response. Metabolite levels found in the host during an ongoing infection could provide valuable information on the pathogenesis and/or identify deregulated metabolic pathway that can be potential candidates for treatment and being potential specific biomarkers of the disease. To gain more insight into those aspects in Chagas disease, we performed an unprecedented metabolomic analysis in heart and plasma of mice infected with T. cruzi. Many metabolic pathways were profoundly affected by T. cruzi infection, such as glucose uptake, sorbitol pathway, fatty acid and phospholipid synthesis that were increased in heart tissue but decreased in plasma. Tricarboxylic acid cycle was decreased in heart tissue and plasma whereas reactive oxygen species production and uric acid formation were also deeply increased in infected hearts suggesting a stressful condition in the heart. While specific metabolites allantoin, kynurenine and p-cresol sulfate, resulting from nucleotide, tryptophan and phenylalanine/tyrosine metabolism, respectively, were increased in heart tissue and also in plasma. These results provide new valuable information on the pathogenesis of acute Chagas disease, unravel several new metabolic pathways susceptible of clinical management and identify metabolites useful as potential specific biomarkers for monitoring treatment and clinical severity in patients. Chagas disease, caused by Trypanosoma cruzi, is the most common cause of cardiomyopathy in Latin America. After the acute phase myocarditis, the disease becomes asymptomatic, and many years later some patients may develop Chagas cardiomyopathy. Treatment is available, but causes side effects. Thus, new drugs are needed, but there are no good tools to assess treatment efficacy. We performed the first global metabolomics analysis in heart tissue and plasma from mice infected with T. cruzi along the infection. We have identified more than 200 biochemicals (around 2/3 of total) that significantly differed in heart and 100 (around 1/3) in plasma. Some of those show extremely marked and highly significant differences. More importantly, our results unravel many new aspects of metabolic alterations that can be useful for: a) better understanding the pathogenesis of this disease; b) provide new clinic-pathological data of T. cruzi infection that can be potentially used for a better clinical management of Chagasic patients; c) define several metabolites as potential biomarkers of this disease. Thus, our study identifies common biomarkers of cardiomyopathy but more importantly specific candidate biomarkers of acute Chagas Disease Cardiomyopathy, not observed in a clinically similar disease Idiopathic Dilated Cardiomiopathy. Allantoin, kynurenine and p-cresol sulfate, that can be easily detected in serum, are highly promising candidates. In summary, we think our results would help to better understand the pathogenesis and management of the disease and offer new candidate biomarkers for monitoring the severity of the disease and treatment efficacy.

2 October 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
FCFrancisco Callejas-Hernández
Francisco Callejas-Hernández
ARAlberto Rastrojo
Alberto Rastrojo
CCCristina Poveda Cuevas
Cristina Poveda Cuevas
JCJuan Cuadros-González
Juan Cuadros-González
MFManuel Fresno
Manuel Fresno
Chagas disease is a complex illness caused by the protozoan Trypanosoma cruzi displaying highly diverse clinical outcomes. In this sense, the genome sequence elucidation and comparison between strains may lead to disease understanding. Here, two new T. cruzi strains, have been sequenced, Y using Illumina and Bug2148 using PacBio, assembled, analyzed and compared with the T. cruzi annotated genomes available to date. The assembly stats from the new sequences show effective improvement of T. cruzi genome over the actual ones. Such as, the largest contig assembled (1.3 Mb in Bug2148) in de novo attempts and the highest mean assembly coverage (71X for Y). Our analysis reveals a new genomic expansion and greater complexity for those multi-copy gene families related to infection process and disease development, such as Trans-sialidases, Mucins and Mucin Associated Surface Proteins, among others. On one side, we demonstrate that multi-copy gene families are located near telomeric regions of the “chromosome-like” 1.3 Mb contig assembled of Bug2148, where they likely suffer high evolutive pressure. On the other hand, we identified several strain-specific single copy genes that might help to understand the differences in infectivity and physiology among strains. In summary, our results indicate that T. cruzi has a complex genomic architecture that may have promoted its evolution.

21 October 2021 in Protein Expression and Purification
Verified
Journal Article
Open access
WCWen-Hsiang Chen
Wen-Hsiang Chen
JPJeroen Pollet
Jeroen Pollet
USUlrich Strych
Ulrich Strych
JLJungsoon Lee
Jungsoon Lee
ZLZhuyun Liu
Zhuyun Liu
MBMaria Bottazzi
Maria Bottazzi
SARS-CoV-2 protein subunit vaccines are currently being evaluated by multiple manufacturers to address the global vaccine equity gap, and need for low-cost, easy to scale, safe, and effective COVID-19 vaccines. In this paper, we report on the generation of the receptor-binding domain RBD203-N1 yeast expression construct, which produces a recombinant protein capable of eliciting a robust immune response and protection in mice against SARS-CoV-2 challenge infections. The RBD203-N1 antigen was expressed in the yeast Pichia pastoris X33. After fermentation at the 5 L scale, the protein was purified by hydrophobic interaction chromatography followed by anion exchange chromatography. The purified protein was characterized biophysically and biochemically, and after its formulation, the immunogenicity was evaluated in mice. Sera were evaluated for their efficacy using a SARS-CoV-2 pseudovirus assay. The RBD203-N1 protein was expressed with a yield of 492.9 ± 3.0 mg/L of fermentation supernatant. A two-step purification process produced a >96% pure protein with a recovery rate of 55 ± 3% (total yield of purified protein: 270.5 ± 13.2 mg/L fermentation supernatant). The protein was characterized to be a homogeneous monomer that showed a well-defined secondary structure, was thermally stable, antigenic, and when adjuvanted on Alhydrogel in the presence of CpG it was immunogenic and induced high levels of neutralizing antibodies against SARS-CoV-2 pseudovirus. The characteristics of the RBD203-N1 protein-based vaccine show that this candidate is another well suited RBD-based construct for technology transfer to manufacturing entities and feasibility of transition into the clinic to evaluate its immunogenicity and safety in humans.

1 May 2016 in Acta Tropica
Verified
Journal Article
Closed access
AMAngela Martinez-Perez
Angela Martinez-Perez
CCCristina Poveda Cuevas
Cristina Poveda Cuevas
JRJuan David Ramírez
Juan David Ramírez
FNFrancesca Norman
Francesca Norman
Núria GironèsNúria Gironès
Núria Gironès
RLRogelio López-Vélez
Rogelio López-Vélez